# A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

> **NCT02705963** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Trametinib
- **DRUG:** Trametinib
- **DRUG:** Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)

## Key facts

- **NCT ID:** NCT02705963
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-20
- **Primary completion:** 2019-08-29
- **Final completion:** 2019-08-29
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02705963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02705963, "A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02705963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*